OTCMKTS:NVTRQ Nuvectra (NVTRQ) Stock Price, News & Analysis → Like Investing in Big Tech in the Early 2000s? (From Manward Press) (Ad) Free NVTRQ Stock Alerts $0.02 -0.01 (-25.00%) (As of 06/2/2020) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.0150▼$0.015052-Week Range$0.01▼$4.30Volume382,600 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nuvectra alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Nuvectra Stock (OTCMKTS:NVTRQ)Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.Read More NVTRQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTRQ Stock News HeadlinesJune 6, 2024 | americanbankingnews.comNuvectra (OTCMKTS:NVTRQ) versus BrainsWay (NASDAQ:BWAY) Head-To-Head AnalysisAugust 1, 2023 | investing.comImasen Electric Industrial Co Ltd (7266)March 4, 2022 | benzinga.comGlobal Nerve Repair & Regeneration Market (2021 to 2026) - by Product, Application and Geography - Benzin - BenzingaMarch 2, 2022 | businesswire.comOutlook on the Nerve Repair & Regeneration Global Market to 2026 - Featuring Medtronic, Abbott Laboratories and LivaNova Among Others - ResearchAndMarkets.com - Business WireFebruary 17, 2022 | globenewswire.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - GlobeNewswireFebruary 17, 2022 | stockhouse.comInteger Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021 - StockhouseFebruary 15, 2022 | benzinga.comGlobal Bioelectric Medicine Market (2020 to 2030) - by Product Type, End-user and Region - Benzinga - BenzingaFebruary 8, 2022 | globenewswire.comGlobal Spinal Cord Stimulation Market (2021 to 2026) - by Product, Disease, End-user and Geography - GlobeNewswireDecember 20, 2021 | benzinga.comGlobal Spinal Cord Stimulation Market Research Report 2021 - Benzinga - BenzingaDecember 15, 2021 | streetinsider.comForm DEF 14A MERIDIAN BIOSCIENCE INC For: Jan 26 - StreetInsider.comOctober 28, 2021 | globenewswire.comInteger Holdings Corporation Reports Third Quarter 2021 Results - GlobeNewswireSeptember 17, 2021 | bizjournals.comAfter 3 years without a CEO, Redmond startup Kymeta formalizes leadership structure - Puget Sound Business Journal (Seattle)July 29, 2021 | globenewswire.comInteger Holdings Corporation Reports Second Quarter 2021 Results - GlobeNewswireSee More Headlines Receive NVTRQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectra and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/29/2018Today6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:NVTRQ Previous SymbolNASDAQ:NVTRV CUSIPN/A CIK1648893 Webwww.nuvectramed.com Phone214-474-3103FaxN/AEmployees197Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Fred B. Parks Ph.D. (Age 72)CEO & Director Mr. Joseph Paul Hanchin (Age 57)Pres Mr. Walter Z. Berger (Age 63)COO, CFO & Exec. VP Ms. Jennifer J. Kosharek (Age 38)VP, Controller & Principal Accounting Officer Mr. Benjamin TranchinaChief Technology OfficerKey CompetitorsAdynxxOTCMKTS:ADYXCalmare TherapeuticsOTCMKTS:CTTCDex LiquidatingOTCMKTS:DXTRQEndologixOTCMKTS:ELGXQHypertension DiagnosticsOTCMKTS:HDIIView All Competitors NVTRQ Stock Analysis - Frequently Asked Questions How have NVTRQ shares performed in 2024? Nuvectra's stock was trading at $0.0150 on January 1st, 2024. Since then, NVTRQ stock has increased by 0.0% and is now trading at $0.0150. View the best growth stocks for 2024 here. How were Nuvectra's earnings last quarter? Nuvectra Corp (OTCMKTS:NVTRQ) released its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.01. The firm had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. How do I buy shares of Nuvectra? Shares of NVTRQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NVTRQ) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectra Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.